Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of dermatological science (Amsterdam)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jdermsci.2016.10.006PMID 27771229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• From melanocytes to melanomas

  2016cited by this paper
• NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand

  2016influential reference
• Neoantigens in cancer immunotherapy

  2015cited by this paper
• Genomic Classification of Cutaneous Melanoma.

  2015cited by this paper
• The Genetic Evolution of Melanoma from Precursor Lesions.

  2015cited by this paper
• Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma.

  2015cited by this paper
• Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.

  2015cited by this paper
• The odds of immunotherapy success

  2015cited by this paper
• Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

  2015cited by this paper
• Mutational Heterogeneity in Melanoma: An Inconvenient Truth.

  2015cited by this paper
• BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.

  2015cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.

  2014cited by this paper
• Melanoma: clinical features and genomic insights.

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

  2014cited by this paper
• BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• Melanomas of unknown primary have a mutation profile consistent with cutaneous sun‐exposed melanoma

  2013cited by this paper
• Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations

  2013cited by this paper
• Mutations of the EPHB6 Receptor Tyrosine Kinase Induce a Pro-Metastatic Phenotype in Non-Small Cell Lung Cancer

  2012cited by this paper
• A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• Molecular Diagnostics

  2011cited by this paper
• Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A et al.. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364

  2006cited by this paper
• Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

  2006cited by this paper
• High frequency of BRAF mutations in nevi

  2003cited by this paper

• BRAF V600E Mutation in Malignant Melanoma—A Romanian Research Experience

  2024cites this paper
• Genetic Concordance in Primary Cutaneous Melanoma and Matched Metastasis: A Systematic Review and Meta-Analysis

  2023cites this paper
• BRAF Immunoexpression Can Be Intralesionally Heterogeneous but BRAF V600E Mutation Status Is Intralesionally Homogeneous and Interlesionally Concordant in Melanoma: A Study of 140 Lesions From 98 Patients

  2022cites this paper
• Intertumor and intratumor heterogeneity of PIK3CA mutations in extramammary Paget’s disease

  2022cites this paper
• Clinical Utility of Next-generation Sequencing in Real-world Cases: A Single-institution Study of Nine Cases

  2022cites this paper
• BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

  2021cites this paper
• Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma

  2021cites this paper
• The human melanoma proteome atlas—Defining the molecular pathology

  2021cites this paper
• Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.

  2021cites this paper
• Distribution and clinical role of KIT gene mutations in melanoma according to subtype. A study on 492 Spanish patients

  2021cites this paper
• BRAF Heterogeneity in Melanoma

  2021cites this paper
• Concordance and Discordance Rates of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)V600E Status in Metastatic against Primary Lesion of Melanoma: A Meta-analysis

  2020cites this paper
• Expression of the NEK family in normal and cancer tissue: an immunohistochemical study

  2020cites this paper
• Checking NEKs: Overcoming a Bottleneck in Human Diseases

  2020cites this paper
• Title: High Concordance of BRAF Mutational Status in Matched Primary and Metastatic Melanoma Short Running Title: High Concordance of BRAF in Melanoma List of Authors:

  2020cites this paper
• Transcriptome and cytogenetic profiling analysis of matched in situ/invasive cutaneous squamous cell carcinomas from immunocompetent patients

  2019cites this paper
• Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis

  2019cites this paper
• Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma

  2019cites this paper
• NEK5 interacts with topoisomerase IIβ and is involved in the DNA damage response induced by etoposide

  2019cites this paper
• The clinical significance of KIT mutations in melanoma: a meta-analysis

  2018cites this paper
• High concordance of BRAF mutational status in matched primary and metastatic melanoma

  2018influential citation
• Cancer risk susceptibility loci in a Swedish population

  2017cites this paper
• Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.

  2017cites this paper
• Intratumor and Intertumor Heterogeneity in Melanoma

  2017cites this paper